Shares of Sun Pharmaceutical Industries remained in focus on Tuesday, May 27, with brokerages continuing to maintain a constructive outlook on the pharmaceutical major, driven by its specialty business expansion, steady India formulations growth, and strong product pipeline.
The stock was trading at Rs 1,841.80, marginally higher by 0.05% during the session. It touched an intraday high of Rs 1,882 and a low of Rs 1,830. The stock’s 52 week high stands at Rs 1,916.60, while the 52 week low is Rs 1,548. Sun Pharma’s market capitalisation currently stands at around Rs 4.42 lakh crore.
Brokerages remain optimistic on the company’s long-term earnings visibility, supported by continued traction in its specialty portfolio and stable domestic formulations business. Analysts also highlighted that Sun Pharma continues to benefit from improving margins and a diversified global product basket.
Several brokerage firms believe the company is well placed to sustain growth momentum through specialty therapies, dermatology products, and complex generics across global markets.
The India business continues to remain a key growth driver for the company, while exports and specialty products are expected to support profitability going forward.
Sun Pharma share price target
Brokerages tracking Sun Pharma remain positive on the stock amid expectations of continued earnings growth, healthy specialty sales, and margin stability.
Analysts also expect the company’s expanding specialty portfolio and product launches to remain key catalysts for future growth, while its strong balance sheet and leadership position in the domestic pharmaceutical market continue to support sentiment around the stock.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.